Abstract
Over the last two decades proteins have become increasingly important in human therapy and diagnosis. Engineering therapeutic proteins through improving their biological activity and stability has been a major interest in our group. In this mini-review we summarize our research on three proteins with pharmaceutical potential – serine protease inhibitor from squash seeds (CMTI), bovine pancreatic trypsin inhibitor (BPTI), and human fibroblast growth factor 1 (FGF1). To improve the functional properties of these proteins we used multiple techniques such as homology approach, rational design, total chemical synthesis, site-directed mutagenesis and phage display. The physicochemical properties of the obtained protein variants were evaluated using protein crystallography, spectroscopic techniques, enzymatic assays, stability measurements as well as numerous biological tests.
Keywords: Protein engineering, protein therapeutics, protease inhibitors, squash inhibitors, BPTI, FGF1, protein stability, human therapy and diagnosis, homology approach, numerous biological tests, Hageman factor, pharmacological properties, antimicrobial peptides, heparan sulfate proteoglycans (HSPGs), heparans (HS)
Current Pharmaceutical Biotechnology
Title: Tailoring Small Proteins Towards Biomedical Applications
Volume: 12 Issue: 11
Author(s): Malgorzata Zakrzewska, Anna Szlachcic and Jacek Otlewski
Affiliation:
Keywords: Protein engineering, protein therapeutics, protease inhibitors, squash inhibitors, BPTI, FGF1, protein stability, human therapy and diagnosis, homology approach, numerous biological tests, Hageman factor, pharmacological properties, antimicrobial peptides, heparan sulfate proteoglycans (HSPGs), heparans (HS)
Abstract: Over the last two decades proteins have become increasingly important in human therapy and diagnosis. Engineering therapeutic proteins through improving their biological activity and stability has been a major interest in our group. In this mini-review we summarize our research on three proteins with pharmaceutical potential – serine protease inhibitor from squash seeds (CMTI), bovine pancreatic trypsin inhibitor (BPTI), and human fibroblast growth factor 1 (FGF1). To improve the functional properties of these proteins we used multiple techniques such as homology approach, rational design, total chemical synthesis, site-directed mutagenesis and phage display. The physicochemical properties of the obtained protein variants were evaluated using protein crystallography, spectroscopic techniques, enzymatic assays, stability measurements as well as numerous biological tests.
Export Options
About this article
Cite this article as:
Zakrzewska Malgorzata, Szlachcic Anna and Otlewski Jacek, Tailoring Small Proteins Towards Biomedical Applications, Current Pharmaceutical Biotechnology 2011; 12 (11) . https://dx.doi.org/10.2174/138920111798376905
DOI https://dx.doi.org/10.2174/138920111798376905 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Functional PLGA NPs for Oral Drug Delivery: Recent Strategies and Developments
Mini-Reviews in Medicinal Chemistry The Treatment of Chronic Hepatitis C not Responding to Interferon
Current Pharmaceutical Design Nutrition as a Health Determinant in Elderly Patients
Current Medicinal Chemistry Development of Proteinase-Activated Receptor 1 Antagonists as Therapeutic Agents for Thrombosis, Restenosis and Inflammatory Diseases
Current Pharmaceutical Design Drug Transporters and Multiple Drug Resistance in the Most Common Pediatric Solid Tumors
Current Drug Metabolism Biomolecular Pathogenesis of Borderline Ovarian Tumors: Focusing Target Discovery Through Proteogenomics
Current Cancer Drug Targets Editorial: New Therapetic Approaches in the Management of Ischemia Reperfusion Injury and Cardiometabolic Diseases: Opportunities and Challenges
Current Drug Targets Clinical Immunotherapy of B-Cell Malignancy Using CD19-Targeted CAR T-Cells
Current Gene Therapy Biphasic Vesicles for Topical Delivery of Interferon Alpha in Human Volunteers and Treatment of Patients with Human Papillomavirus Infections
Current Drug Delivery Novel Possible Pharmaceutical Research Tools: Stem Cells, Gene Delivery and their Combination
Current Pharmaceutical Design Vitamin-D in the Immune System: Genomic and Non-Genomic Actions
Mini-Reviews in Medicinal Chemistry Development of Novel Genomic Blood Biomarkers for Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Spiro-Lactams as Novel Antimicrobial Agents
Current Topics in Medicinal Chemistry Pharmacogenetic Aspects in Therapeutic Management of Subfoveal Choroidal Neovascularisation: Role of Factor XIII-A 185 T-Allele
Current Drug Targets Patterns of NSAIDs Use in Palestinian Mid-Territories: A Prospective Study of Ambulatory Patients in Outpatient Pharmacies
Current Clinical Pharmacology Ulcerative Colitis: Pathogenesis
Current Drug Targets Advances in Fish Cytokine Biology Give Clues to the Evolution of a Complex Network
Current Pharmaceutical Design New Approaches to Target the Androgen Receptor and STAT3 for Prostate Cancer Treatments
Mini-Reviews in Medicinal Chemistry Current Ocular Drug Delivery Challenges for N-acetylcarnosine: Novel Patented Routes and Modes of Delivery, Design for Enhancement of Therapeutic Activity and Drug Delivery Relationships
Recent Patents on Drug Delivery & Formulation Anticancer Activity of the Ascidian Polyclinum Indicum against Cervical Cancer Cells (HeLa) Mediated through Apoptosis Induction
Medicinal Chemistry